Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2009 Jan 9;136(1):17-9.
doi: 10.1016/j.cell.2008.12.032.

Who benefits from granulomas, mycobacteria or host?

Affiliations
Comment

Who benefits from granulomas, mycobacteria or host?

Tyler D Bold et al. Cell. .

Abstract

By investigating host-pathogen interactions in zebrafish using intravital imaging, Davis and Ramakrishnan (2009) provide evidence that aggregates of immune cells known as granulomas, long thought to constrain mycobacterial infection, may instead facilitate its spread.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Stages of Granuloma Formation in Tuberculosis
Findings by Davis and Ramakrishnan (2009) explain the initial stage of tuberculosis, which is characterized by expansion of the bacterial population in the absence of adaptive immunity. Bacterial multiplication and spread are facilitated by formation of the nascent granuloma. Infected macrophages undergo apoptosis and recruit uninfected macrophages to the site. These recruited macrophages phagocytose the remnants of infected cells and their bacterial contents. Some newly infected macrophages egress to seed secondary granuloma formation. When initiation of adaptive immunity eventually occurs, CD4+ and CD8+ effector T lymphocytes are recruited to infected tissue and curtail bacterial growth. Although essential for control of the infection, adaptive immunity cannot eradicate it. The mature granuloma represents an equilibrium between virulent mycobacteria and the host immune response.

Comment on

References

    1. Adams DO. Am J Pathol. 1976;84:164–192. - PMC - PubMed
    1. Clay H, Volkman HE, Ramakrishnan L. Immunity. 2008;29:283–294. - PMC - PubMed
    1. Davis JM, Clay H, Lewis JL, Ghori N, Herbomel P, Ramakrishnan L. Immunity. 2002;17:693–702. - PubMed
    1. Davis JM, Ramakrishnan L. Cell. 2009 this issue. - PMC - PubMed
    1. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN. Immunity. 2008;28:271–284. - PMC - PubMed